Patrick Pilie, MD, discusses the impact of adiposity on response to androgen signaling inhibition in patients with metastatic castration-resistant prostate cancer.
Patrick Pilie, MD, an assistant professor in the Department of Genitourinary Medical Oncology of the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, discusses the impact of adiposity on response to androgen signaling inhibition in patients with metastatic castration-resistant prostate cancer (mCRPC).
Men with higher visceral adiposity, and subcutaneous adiposity, experience better responses to androgen ablative therapy, Pilie says. Additionally, although obesity and a body mass index of 26 or higher was predictive of better outcomes with this treatment, even patients who were not obese but had higher adiposity scores achieved better responses than those with lower adiposity scores, Pilie adds.
This was biologically consistent, even in the group that was not obese; thus these results demonstrate a more specific measurement of metabolic arrangements and adiposity using this imaging technique, Pilie concludes.